Access type

Forgot your password? Click here

DMP_ForgotOK Close


If you are a doctor or a journalist not yet registered at the Dompé reserved areas, click here to fill in the form.



Company of the year for innovation in research and biotechnology

Dompé receives the Le Fonti 2016 international award

    Milan, 27th June 2016.. The ability to innovate in the field of biotechnology and open innovation in research on rare and orphan diseases. These are precisely the two hallmarks of the Dompé Group that have earned it the Le Fonti 2016 award as company of the year for "Innovation, Research and Biotechnology” at the award ceremony held at Palazzo Mezzanotte in Milan.

    According to the explanatory statement, the award was given "for innovation demonstrated in the field of biotechnology and for the cutting-edge research in the field of rare diseases. For the "open innovation" approach that has involved a network of over 200 international research centres." This testifies to the value of the path in innovation taken by Dompé at both national and international level through a research network engaged in the study of therapeutic solutions for rare or orphan diseases and through the opening of new branches in the United States and in Europe.

    “Receiving an accolade that acknowledges the value of our innovation is for us a source of great pride and testifies to the fact that we have made the right strategic choice: to concentrate our commitment in biotech research on areas with a high medical need and at the same time to focus on the incremental innovation of our Primary Care products – stated Eugenio Aringhieri, Dompé CEO. “We have chosen our ‘playing field’ in an extremely challenging landscape both from the point of view of production and in the field of research and development in which the very concept of ‘open innovation’ and of the global network can yield results for the health needs of thousands of patients around the world. An example of this is the rhNGF molecule: the fruit of an Italian intuition, that of Nobel Prize winner Rita Levi Montalcini, it was studied in our laboratories in L'Aquila and is now the subject of international clinical trials.”

    Now in its sixth edition, the Le Fonti International Award saw the participation of over 100 companies from different industries, for a total of 50 awards.